Try ibuprofen plus growth factor and stem-cell mobilizer for X-CGD
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a combination of medicines to help your body release (“mobilize”) stem cells for future treatment in people with X-linked chronic granulomatous disease (X-CGD). If it works well and is safe for you, it may make stem-cell collection easier and more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic diagnosis of X-CGD
- You are between 18 and 45 years old
- You are able to do daily activities at a good level (Karnofsky score above 80)
- Your heart, kidney, liver, and lungs work well enough for the study medicines
- You have no history of blood clots from a clotting disorder (negative thrombophilia test and no prior thrombotic events)
- You can sign informed consent and agree to study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
This trial tests an intensive stem cell transplant approach for people with chronic granulomatous disease (CGD). The study aims to improve outcomes by preparing the body for a donor stem cell graft and using immune “brakes” to reduce immune problems.
This trial tests a gene therapy that uses base-edited stem cells to treat X-SCID, a genetic immune disorder. It may help improve immune function and reduce infections in patients who still have low immune cells or severe infections despite previous treatments.
This trial tests a lentiviral gene therapy to improve immune function in people with CGD, a condition where the body can’t fight certain infections well. It may help by addressing the underlying genetic problem, but it also requires a procedure to collect immune cells and special “conditioning” medicines beforehand.
This trial tests a new gene editing treatment called PM359 for people with a specific type of chronic granulomatous disease (CGD) caused by a delGT mutation in the NCF1 gene. The goal is to see if it's safe and helps fight infections and inflammation.
Hear when a new Chronic Granulomatous Disease X-linked (X-CGD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.